← Back to Clinical Trials
Recruiting NCT07294274

NCT07294274 Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07294274
Status Recruiting
Phase
Sponsor Min Su
Condition Post-stroke Depression
Study Type OBSERVATIONAL
Enrollment 488 participants
Start Date 2025-11-01
Primary Completion 2026-07-20

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Group patients based on whether they have been diagnosed with PSD.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 488 participants in total. It began in 2025-11-01 with a primary completion date of 2026-07-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Post-stroke depression (PSD) is the most common neuropsychiatric disorder after a stroke, with an incidence rate of 20% to 60%. PSD is not only associated with higher mortality rates, poorer recovery, more obvious cognitive impairments, greater economic burdens, and lower quality of life, but also brings additional medical expenses and care pressure to families. Society also needs to bear higher medical costs. Currently, the early diagnosis of PSD is difficult, which may lead to poor prognosis after stroke. This study aims to utilize machine learning technology to integrate multi-dimensional indicators of patients with ischemic stroke, establish a risk prediction model for PSD, and assist in early, accurate, and individualized assessment of PSD risk in clinical practice.

Eligibility Criteria

Inclusion Criteria: * Patients with acute ischemic stroke; * Admission within 7 days of symptom onset; * The patient and/or the family members sign a written informed consent form. Exclusion Criteria: * Confusion of consciousness,severe cognitive impairment, etc * Individuals with a history of depression, schizophrenia, bipolar disorder, etc; * Individuals unable to participate in neuropsychological examinations due to hearing im pairments, lack of coordination, or neurological deficits, including se vere aphasia.

Contact & Investigator

Central Contact

Yanping Zhang

✉ zhangyp8415@163.com

📞 86+15223049366

Frequently Asked Questions

Who can join the NCT07294274 clinical trial?

This trial is open to participants of all sexes, studying Post-stroke Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07294274 currently recruiting?

Yes, NCT07294274 is actively recruiting participants. Contact the research team at zhangyp8415@163.com for enrollment information.

Where is the NCT07294274 trial being conducted?

This trial is being conducted at Chongqing, China.

Who is sponsoring the NCT07294274 clinical trial?

NCT07294274 is sponsored by Min Su. The trial plans to enroll 488 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology